Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 4/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992227 | 0.87 | HTR2B (0.59) | HTR2BSMN1; SMN2POLBMAPTHSD17B10 | |
| SCHEMBL24067409 | 0.84 | HTR2B (0.59) | HTR2BSMN1; SMN2POLBMAPTHSD17B10 | |
| SCHEMBL19408169 | 0.82 | HPGDS (0.57) | HTR2BSMN1; SMN2POLB | |
| SCHEMBL762565 | 0.82 | HPGDS (0.57) | HTR2BSMN1; SMN2POLB | |
| SCHEMBL739188 | 0.82 | HPGDS (0.57) | HTR2BSMN1; SMN2POLB | |
| SCHEMBL23130983 | 0.79 | GPR119 (0.50) | MAPT | |
| SCHEMBL742770 | 0.79 | HTR2B (0.50) | HTR2BSMN1; SMN2POLBMAPTHSD17B10 | |
| SCHEMBL21714120 | 0.79 | UBE2M (0.51) | KMT2ASMN1; SMN2POLBMAPTHSD17B10 | |
| SCHEMBL21714287 | 0.78 | KDM4E (0.55) | KMT2APOLB | |
| SCHEMBL21714546 | 0.77 | GPR119 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | claimed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | claimed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | E-THERAPEUTICS PLC (GB) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | SHH, GLI1, SMO | KMT2A 1842/4885HTR2B 3805/4885USP2 2488/4885 |
| US-20200055847-A1 | MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY | SHH, GLI1, SMO | KMT2A 1855/4885HTR2B 3768/4885USP2 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.